Download MendeleyOptimization of Indazole-Based GSK-3 Inhibitors with Mitigated hERG Issue andIn VivoActivity in a Mood Disorder Model.
Prati, F., Buonfiglio, R., Furlotti, G., Cavarischia, C., Mangano, G., Picollo, R., Oggianu, L., di Matteo, A., Olivieri, S., Bovi, G., Porceddu, P.F., Reggiani, A., Garrone, B., Di Giorgio, F.P., Ombrato, R.(2020) ACS Med Chem Lett 11: 825-831
- PubMed: 32435391 Search on PubMedSearch on PubMed Central
- DOI: https://doi.org/10.1021/acsmedchemlett.9b00633
- Primary Citation Related Structures:
6TCU - PubMed Abstract:
Bipolar disorders still represent a global unmet medical need and pose a requirement for novel effective treatments. In this respect, glycogen synthase kinase 3β (GSK-3β) aberrant activity has been linked to the pathophysiology of several disease conditions, including mood disorders. Therefore, the development of GSK-3β inhibitors with good in vivo efficacy and safety profile associated with high brain exposure is required. Accordingly, we have previously reported the selective indazole-based GSK-3 inhibitor 1 , which showed excellent efficacy in a mouse model of mania. Despite the favorable preclinical profile, analog 1 suffered from activity at the hERG ion channel, which prevented its further progression. Herein, we describe our strategy to improve this off-target liability through modulation of physicochemical properties, such as lipophilicity and basicity. These efforts led to the potent inhibitor 14 , which possessed reduced hERG affinity, promising in vitro ADME properties, and was very effective in a mood stabilizer in vivo model.
- Angelini Pharma S.p.A., Viale Amelia, 70, 00181 Rome, Italy.
Organizational Affiliation:
